The Swiss biotech company is making significant progress in the research and development of treatments to fight bacterial resistance, a real and present Global Health issue. BioVersys has been striving to make new drugs effective against bacterial infections. Antibiotics are among the most important and oldest medical discoveries, saving millions of lives each year. But […]
BioVersys is featured in a Forbes France special Read More »
Basel, Switzerland, December 05, 2018. 09:00 CET Dr. Glenn E. Dale Appointed Chief Development Officer of BioVersys BioVersys is strengthening its executive management team with the appointment of Dr. Glenn E. Dale as Chief Development Officer as of February 1st, 2019. He will lead clinical development activities and brings 25 years of R&D experience and
Dr. Glenn E. Dale Appointed CDO of BioVersys Read More »
BioVersys together with BioSystems Technology and Voxcan announced funding – € 840,000 over a 3-year period – by Eurostars for IMPACT2, a new translational AMR platform that will expedite the development of novel new medicines in the fight against antimicrobial resistance. There is an urgent need for new treatments against untreatable infections caused by drug-resistant
Fresh funds to fuel the fight against drug-resistant bacteria Read More »
Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 – an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and Voxcan announce funding for a
Biosystems Technology, BioVersys and Voxcan announce funding by Eurostras Read More »
Basel, Switzerland, November 15, 2018. 09:00 CET BioSystems Technology, BioVersys and Voxcan join forces to establish IMPACT2 – an Innovative Multifaceted Platform for Antimicrobial Commercialisation Transformation Powered by Eurostars – a joint programme co-funded by EUREKA member countries and the European Union Horizon 2020 Framework Programme BioSystems Technology, BioVersys and Voxcan announce funding for a
Eurostars Funds IMPACT2 To Establish A Break-Through Translational AMR Platform Read More »
An interesting and informative report on bacteria and antibiotic resistance, including an interview with Marc Gitzinger. The report starts at 10:25 Link to Article
An interesting and informative report on bacteria and antibiotic resistance Read More »
BioVersys s’implante à Lille pour intensifier la recherche et le développement de nouveaux antibiotiques afin de combattre la résistance bactérienne, en collaboration avec des équipes de recherche lilloises En collaboration avec l’Institut Pasteur de Lille, l’Inserm, le CNRS, l’Université de Lille et la SATT Nord, BioVersys, société biopharmaceutique suisse, va renforcer la recherche et le
BioVersys and Institut Pasteur de Lille Working Together Read More »
The European Medicines is proposing to update its two existing guidelines on the clinical evaluation of medicines for treating bacterial infections and merge them into a single core document. The new document would clarify, among other things, considerations for the acceptance of single pivotal studies to support infection-site specific indications and pathogen-specific indications. A draft
Increase In Antibacterial R&D Prompts EMA Proposal For Improved Guidance Read More »
Basel, November 20, 2017 BioVersys AG announced today that it has successfully closed a Series A2 financing round of CHF 5 million with existing private investors. “We would like to thank our investors for their ongoing support. The funds will be used to prepare for clinical development with BioVersys’ lead project directed at Tuberculosis and
BioVersys AG successfully closes Series A2 financing round Read More »
Tuberkulose-Erreger sind zunehmend unempflindlich gegen Antibiotika. “Wir in der Schweiz können nicht sagen, Tuberkulose ginge uns nichts an” Marc Gitzinger, BioVersys AG Link to Article
Beobachter 10/2017: Die Tuberkulose überlistet. Ein Interview mit Marc Gitzinger Read More »
